These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model. Wang Z; Halbert CL; Lee D; Butts T; Tapscott SJ; Storb R; Miller AD Gene Ther; 2014 Apr; 21(4):363-70. PubMed ID: 24500525 [TBL] [Abstract][Full Text] [Related]
27. Ocular Inflammatory Response to Intravitreal Injection of Adeno-Associated Virus Vector: Relative Contribution of Genome and Capsid. Timmers AM; Newmark JA; Turunen HT; Farivar T; Liu J; Song C; Ye GJ; Pennock S; Gaskin C; Knop DR; Shearman MS Hum Gene Ther; 2020 Jan; 31(1-2):80-89. PubMed ID: 31544533 [TBL] [Abstract][Full Text] [Related]
28. Complement is an essential component of the immune response to adeno-associated virus vectors. Zaiss AK; Cotter MJ; White LR; Clark SA; Wong NC; Holers VM; Bartlett JS; Muruve DA J Virol; 2008 Mar; 82(6):2727-40. PubMed ID: 18199646 [TBL] [Abstract][Full Text] [Related]
29. Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hinderer C; Katz N; Buza EL; Dyer C; Goode T; Bell P; Richman LK; Wilson JM Hum Gene Ther; 2018 Mar; 29(3):285-298. PubMed ID: 29378426 [TBL] [Abstract][Full Text] [Related]
30. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A. Long BR; Veron P; Kuranda K; Hardet R; Mitchell N; Hayes GM; Wong WY; Lau K; Li M; Hock MB; Zoog SJ; Vettermann C; Mingozzi F; Schweighardt B Mol Ther; 2021 Feb; 29(2):597-610. PubMed ID: 33309883 [TBL] [Abstract][Full Text] [Related]
31. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B. George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433 [TBL] [Abstract][Full Text] [Related]
32. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Martino AT; Suzuki M; Markusic DM; Zolotukhin I; Ryals RC; Moghimi B; Ertl HC; Muruve DA; Lee B; Herzog RW Blood; 2011 Jun; 117(24):6459-68. PubMed ID: 21474674 [TBL] [Abstract][Full Text] [Related]
33. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome. Wu TL; Li H; Faust SM; Chi E; Zhou S; Wright F; High KA; Ertl HC Mol Ther; 2014 Jan; 22(1):42-51. PubMed ID: 24077034 [TBL] [Abstract][Full Text] [Related]
34. AAV as an immunogen. Vandenberghe LH; Wilson JM Curr Gene Ther; 2007 Oct; 7(5):325-33. PubMed ID: 17979679 [TBL] [Abstract][Full Text] [Related]
35. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Manning WC; Zhou S; Bland MP; Escobedo JA; Dwarki V Hum Gene Ther; 1998 Mar; 9(4):477-85. PubMed ID: 9525309 [TBL] [Abstract][Full Text] [Related]
36. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Martino AT; Basner-Tschakarjan E; Markusic DM; Finn JD; Hinderer C; Zhou S; Ostrov DA; Srivastava A; Ertl HC; Terhorst C; High KA; Mingozzi F; Herzog RW Blood; 2013 Mar; 121(12):2224-33. PubMed ID: 23325831 [TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer. Arjomandnejad M; Dasgupta I; Flotte TR; Keeler AM BioDrugs; 2023 May; 37(3):311-329. PubMed ID: 36862289 [TBL] [Abstract][Full Text] [Related]
38. Synergistic inhibition of PARP-1 and NF-κB signaling downregulates immune response against recombinant AAV2 vectors during hepatic gene therapy. Hareendran S; Ramakrishna B; Jayandharan GR Eur J Immunol; 2016 Jan; 46(1):154-66. PubMed ID: 26443873 [TBL] [Abstract][Full Text] [Related]
39. Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction. Shao W; Earley LF; Chai Z; Chen X; Sun J; He T; Deng M; Hirsch ML; Ting J; Samulski RJ; Li C JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925692 [TBL] [Abstract][Full Text] [Related]
40. Bat adeno-associated viruses as gene therapy vectors with the potential to evade human neutralizing antibodies. Li Y; Li J; Liu Y; Shi Z; Liu H; Wei Y; Yang L Gene Ther; 2019 Jun; 26(6):264-276. PubMed ID: 31110296 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]